Home Ingredients Xanthigen® (Fucoxanthin + Pomegranate Seed Oil)
Weight ManagementLiver HealthMetabolic HealthAntioxidant

Xanthigen® (Fucoxanthin + Pomegranate Seed Oil)

Undaria pinnatifida (wakame) + Punica granatum
Evidence Level
Limited
3 Clinical Trials
7 Documented Benefits
2/5 Evidence Score

Branded patented blend from Nektium of wakame brown seaweed (Undaria pinnatifida) extract containing fucoxanthin plus pomegranate seed oil. Abidov 2010 (, Diabetes Obes Metab 12(1):72-81) is the pivotal 16-week RCT in 151 obese premenopausal women (113 with NAFLD, 38 with normal liver fat) — 600 mg/day Xanthigen® (300 mg PSO + 300 mg brown seaweed extract with 2.4 mg fucoxanthin) on 1,800 kcal/day diet. Significant body weight, body fat, and liver fat reductions; resting energy expenditure increased ~400 kcal/day; ALT/AST/GGT reductions in NAFLD subgroup. The 400 kcal/day REE increase via UCP1-mediated thermogenesis is genuinely distinctive among weight-management supplements. Honest caveat: only one published human weight-management trial of this magnitude — independent replication remains limited.

Studied Dose PIVOTAL: 600 mg Xanthigen®/day × 16 weeks (300 mg PSO + 300 mg brown seaweed extract with 2.4 mg fucoxanthin). On 1,800 kcal/day diet (50% carb / 30% protein / 20% fat). Take with food. Pregnancy: avoid. Thyroid medication users: caution (iodine content from brown seaweed).
Active Compound Fucoxanthin (allenic carotenoid from brown seaweed Undaria pinnatifida wakame) + pomegranate seed oil (rich in punicic acid — conjugated linolenic acid). Patented synergistic combination

Benefits

Weight management and visceral fat in obese women

Abidov M et al. 2010 (, Diabetes Obes Metab 12(1):72-81) — 16-week double-blind randomized placebo-controlled trial in 151 non-diabetic obese premenopausal women on 1,800 kcal/day energy-restricted diet. 600 mg/day Xanthigen® (300 mg PSO + 300 mg brown seaweed extract with 2.4 mg fucoxanthin). Significant weight loss, body fat reductions, and ~3 cm waist reduction. No adverse reactions over 16 weeks.

Supported by Trial 1

NAFLD liver fat content reduction

Abidov 2010 enrolled 113 women with NAFLD (liver fat >11%) plus 38 with normal liver fat (<6.5%) — the NAFLD subgroup is particularly important. Liver fat content was reduced; ALT, AST, and GGT plasma levels were reduced — clinically relevant for fatty liver disease where pharmacological options are limited. Particularly compelling intervention given the unmet need in NAFLD.

Supported by Trial 1

Resting energy expenditure increase ~400 kcal/day

Abidov 2010 documented an increase in resting energy expenditure of approximately 400 kcal/day in the active group. Distinctive thermogenic mechanism via fucoxanthin's UCP1-mediated white-to-brown adipose tissue browning — different from caffeine-based stimulant thermogenics. Provides a non-stimulant thermogenic option.

Supported by Trial 1

Blood lipid profile improvements

Abidov 2010 also reported blood lipid profile improvements. Multi-domain metabolic effects align with the proposed multi-mechanism action.

Supported by Trial 1

Inflammatory markers and blood pressure

reported inflammatory marker improvements plus blood pressure improvements. Cardiometabolic-syndrome-relevant endpoints alongside the weight and liver outcomes.

Supported by Trial 1

Synergistic patented combination (mechanism)

The combination provides multi-target weight management benefits beyond either component alone: fucoxanthin (UCP1-mediated thermogenesis) + pomegranate seed oil (punicic acid conjugated linolenic acid + antioxidant + cardiovascular effects). The synergistic positioning differentiates Xanthigen® from generic fucoxanthin or pomegranate seed oil supplements.

Supported by Trial 1, Trial 2

Pomegranate seed oil punicic acid antioxidants

Pomegranate seed oil is rich in punicic acid (a conjugated linolenic acid, 18:3 n-5) supporting cholesterol modulation, insulin sensitivity, and anti-inflammatory effects. Mechanistic complement to fucoxanthin's thermogenic action.

Supported by Trial 2, Trial 1

Mechanism of action

1

Fucoxanthin UCP1-mediated thermogenesis

Fucoxanthin (an allenic carotenoid) induces UCP1 expression in white adipose tissue, driving white-to-brown adipose tissue browning. Browned adipose tissue oxidizes fatty acids for heat rather than ATP, increasing energy expenditure — the mechanism for the observed ~400 kcal/day REE rise. Distinguishing thermogenic mechanism among weight-management supplements.

2

PPARγ and C/EBPs adipogenesis transcription factor down-regulation

Lee 2012 (J Agric Food Chem 60(4):1094-1101) — Xanthigen® suppresses preadipocyte differentiation and adipogenesis through down-regulation of PPARγ and C/EBP transcription factors. Mechanistic basis for the body fat reduction beyond simple thermogenesis.

3

SIRT-1, AMPK, and FoxO pathway modulation

Lee 2012 also documented SIRT-1, AMPK, and FoxO pathway modulation — multi-pathway metabolic regulation including longevity-associated SIRT-1 activation and AMPK-driven fatty acid oxidation.

4

Punicic acid (pomegranate) effects

Pomegranate seed oil punicic acid (conjugated linolenic acid 18:3 n-5) supports cholesterol modulation, insulin sensitivity, and anti-inflammatory effects. Distinct mechanism complementing fucoxanthin's thermogenic action.

5

Fucoxanthin antioxidant activity

Fucoxanthin is a strong singlet oxygen quencher and free radical scavenger. Antioxidant mechanism contributing to the broader metabolic benefits.

6

Hepatoprotective effects

ALT, AST, and GGT improvements in the NAFLD subgroup of Abidov 2010 reflect hepatoprotective activity — likely combining direct fatty acid oxidation effects with anti-inflammatory mechanisms.

Clinical trials

1
Xanthigen® 16-Week NAFLD/Obesity Clinical Trial

Clinical evidence on Xanthigen® (Fucoxanthin + Pomegranate Seed Oil) for the indications and outcomes described.

premenopausal women

Abidov M et al. 2010 (Diabetes Obes Metab 12(1):72-81). 16-week double-blind randomized placebo-controlled trial in 151 non-diabetic obese premenopausal women — 113 with NAFLD (liver fat >11%) plus 38 with normal liver fat (<6.5%). 600 mg/day Xanthigen® on 1,800 kcal/day diet. Significant weight loss, body fat reductions, ~3 cm waist reduction; liver fat reduction in NAFLD subgroup; ALT/AST/GGT reductions; REE increased ~400 kcal/day; blood lipid, inflammatory marker, and blood pressure improvements. No adverse reactions. Foundational human trial supporting both weight management and NAFLD applications.

2
Xanthigen® Adipogenesis Mechanism Study

Clinical evidence on Xanthigen® (Fucoxanthin + Pomegranate Seed Oil) for the indications and outcomes described.

Clinical population described in trial publication.

Lee J et al. 2012 (J Agric Food Chem 60(4):1094-1101). Mechanism study — Xanthigen® suppresses preadipocyte differentiation and adipogenesis through down-regulation of PPARγ and C/EBP transcription factors, plus modulation of SIRT-1, AMPK, and FoxO pathways. Comprehensive molecular characterization supporting the body fat reduction observation.

3
Fucoxanthin Adipocyte Differentiation Suppression (Foundational)

Clinical evidence on Xanthigen® (Fucoxanthin + Pomegranate Seed Oil) for the indications and outcomes described.

Clinical population described in trial publication.

Maeda H et al. 2006 (Int J Mol Med 18(1):147-152). Foundational fucoxanthin pharmacology — fucoxanthin and its metabolite fucoxanthinol suppress adipocyte differentiation in 3T3-L1 cells. Preclinical mechanism work that motivated the Xanthigen® clinical development.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; NO adverse reactions in 16-week Abidov 2010 trial.
GI upset (rare).
Mild iodine content from brown seaweed — caution in iodine-sensitive thyroid conditions.
Pregnancy/lactation: limited data; precautionary avoidance.
Long-term safety: 16-week trial is longest published Xanthigen data.
Allergic reactions in seaweed/seafood-allergic individuals (rare).
Pomegranate-allergy (rare).

Important Drug interactions

Anticoagulants (warfarin, DOACs): theoretical mild antiplatelet effect from pomegranate seed oil — monitor.
Antihypertensives: theoretical mild additive effects via cardiovascular mechanisms.
Thyroid medications (levothyroxine): brown seaweed iodine content — monitor TSH; may need dose adjustment.
Antidiabetic medications: theoretical compatible glucose effects; monitor blood glucose.
Statins: compatible.
Most medications: well-tolerated combination profile.

More Weight Management Ingredients

Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…
Weight Management
Glucomannan (Konjac Root Fiber)
Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Am…
Weight Management
Supresa® (Saffron Extract for Appetite & Crave Control — PLT Health)
Supresa® is PLT Health Solutions' patented saffron (Crocus sativus L.) stigma extract — cl…
Weight Management
Erythritol
Erythritol is a 4-carbon sugar alcohol (polyol) — about 60-70% as sweet as sucrose with es…

Explore Other Ingredients

Antioxidant
Setria® Glutathione
Setria® is Kyowa Hakko's patented reduced L-glutathione (GSH) produced via fermentation —…
Antioxidant
Milk Thistle
Milk thistle, derived from the Silybum marianum plant, contains silymarin, a compound know…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a lipid-soluble compound essential to mitochondrial ATP production…

Frequently asked questions about Xanthigen® (Fucoxanthin + Pomegranate Seed Oil)

What is Xanthigen?

Branded patented blend from Nektium of wakame brown seaweed (Undaria pinnatifida) extract containing fucoxanthin plus pomegranate seed oil. Abidov 2010 (, Diabetes Obes Metab 12(1):72-81) is the pivotal 16-week RCT in 151 obese premenopausal women (113 with NAFLD, 38 with normal liver fat) — 600 mg/day Xanthigen® (300…

What is Xanthigen used for?

Xanthigen is researched primarily for Weight Management, Liver Health, and Metabolic Health. Abidov M et al. 2010 (, Diabetes Obes Metab 12(1):72-81) — 16-week double-blind randomized placebo-controlled trial in 151 non-diabetic obese premenopausal women on 1,800 kcal/day energy-restricted diet.

What is the recommended dosage of Xanthigen?

The clinically studied dose is Pivotal: 600 mg Xanthigen®/day × 16 weeks (300 mg PSO + 300 mg brown seaweed extract with 2.4 mg fucoxanthin). On 1,800 kcal/day diet (50% carb / 30% protein / 20% fat). Take with food. Pregnancy: avoid. Always follow the product label and check with a healthcare provider for personal advice.

Is Xanthigen safe, and does it have side effects?

For most healthy adults, Xanthigen is well tolerated at studied doses. Reported effects can include: Generally well-tolerated; NO adverse reactions in 16-week Abidov 2010 trial. GI upset (rare). It may also interact with some medications. Xanthigen is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Xanthigen interact with any medications?

Possible interactions include: Anticoagulants (warfarin, DOACs): theoretical mild antiplatelet effect from pomegranate seed oil — monitor. Antihypertensives: theoretical mild additive effects via cardiovascular mechanisms. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Xanthigen?

NutraSmarts rates the evidence for Xanthigen as Limited (2 out of 5). It is backed by 3 clinical trials and 2 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(2 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Abidov M, Ramazanov Z, Seifulla R, Grachev S The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat Diabetes, Obesity and Metabolism. 2010;12(1):72-81. doi:10.1111/j.1463-1326.2009.01132.x.PubMedUsed to support: 16-week double-blind RCT of Xanthigen® 600 mg/day (300 mg pomegranate seed oil + 300 mg brown seaweed extract with 2.4 mg fucoxanthin) in 151 obese premenopausal women (113 NAFLD, 38 normal liver fat): significant weight loss (5.5±1.4 kg NAFLD; 4.9±1.2 kg NLF), body fat reduction, decreased liver fat, reduced triglycerides and C-reactive protein, significantly increased resting energy expenditure. Supports all weight management, NAFLD liver fat, REE, and lipid/inflammatory benefits.
  2. Mikami N, Hosokawa M, Miyashita K, Sohma H, Ito YM, Kokai Y Reduction of HbA1c levels by fucoxanthin-enriched akamoku oil possibly involves the thrifty allele of uncoupling protein 1 (UCP1) Journal of Nutritional Science. 2017;6:e5. doi:10.1017/jns.2017.1.PubMedUsed to support: Human RCT of fucoxanthin-enriched oil (the active component in Xanthigen®) in Japanese adults: 2 mg/day fucoxanthin significantly reduced HbA1c vs placebo (p<0.05), particularly in individuals with UCP1 thrifty allele. Supports blood glucose and metabolic marker improvement; note: this paper studies the fucoxanthin component, not the Xanthigen® brand directly.